2016
DOI: 10.1002/pds.3927
|View full text |Cite
|
Sign up to set email alerts
|

Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model

Abstract: The size of the patient population with MM on different lines of therapy and in patient subgroups of interest estimated from this epidemiologic model can be used to assess the number of patients who could benefit from new MM therapies and their corresponding budgetary impact. Copyright © 2016 John Wiley & Sons, Ltd.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
17
0
3

Year Published

2016
2016
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 36 publications
(21 citation statements)
references
References 60 publications
(93 reference statements)
0
17
0
3
Order By: Relevance
“…2,18,19 The estimated world-wide 5-year prevalence is approximately 230,000 patients. 20 In the Western world, the age-standardized incidence has been reported to be approximately 5 cases per 100,000. 21,22 The median age of patients at diagnosis is approximately 66–70 years with 37% of patients being younger than 65 years of age.…”
Section: Multiple Myeloma Epidemiology: Incidence Survival and Racimentioning
confidence: 99%
“…2,18,19 The estimated world-wide 5-year prevalence is approximately 230,000 patients. 20 In the Western world, the age-standardized incidence has been reported to be approximately 5 cases per 100,000. 21,22 The median age of patients at diagnosis is approximately 66–70 years with 37% of patients being younger than 65 years of age.…”
Section: Multiple Myeloma Epidemiology: Incidence Survival and Racimentioning
confidence: 99%
“…Treatment of elderly MM patients at relapse is often challenging, in part due to the fact that the number of therapeutic lines that can be endured is limited compared to younger and fitter patients. 59 Advanced age, coexisting comorbidities, toxicities from previous therapies and an aggressive pattern of relapse may also reduce the spectrum of feasible salvage therapies. 6 The analysis of the risk/benefit ratio of each agent is therefore pivotal to individualize treatment.…”
Section: Treatment Of Relapsed/refractory Elderly MM Patientsmentioning
confidence: 99%
“…Географическионашироковарьируетвразныхрегионах мира и максимальна в индустриализованных районах Австралии, Новой Зеландии, Европы и Северной Америки [7]. Заболеваемость ММ в США всреднемсоставляет4-5новыхслучаев,средипопу-ляцииафроамериканцевможетдостигать9-10забо-левшихна100тыс.населениявгод [8,9].Напротив, встранахВосточнойАзии,вчастностивЯпонии,этот показательнижеинепревышает1,2случаяна100тыс. населениявгод [10].Кстранамснизкойзаболеваемостью ММ относятся Южная Корея (1,4) [11], Китай (1,3) [12]иТайвань (1,8случаяна100тыс.населения вгод) [13].…”
Section: о н к о г е м а т о л о г и я 3 ' 2 017 т о м 1 2 O N C O H unclassified